Breast Cancer

Deep learning model beats breast density for 5-year breast cancer risk, informing supplemental screening decisions and personalized care.

Amid breast cancer surging in women under 50, new data and WISDOM trial results support individualized screening over age-based guidelines.

This FDA approval brings the first heterobifunctional protein degrader for HER2-negative, ESR1-mutant breast cancer, improving PFS after endocrine therapy.

Rani Bansal, MD, discusses breast cancer subtypes, racial disparities in triple-negative disease, self-advocacy for young patients, and diversity in clinical trials.

Experts examined oncology care innovation, access gaps to CAR T-cell therapy, advances in myeloma care, and partnerships in value-based care.

Rani Bansal, MD, explores what's driving the surge in breast cancer in young women and why earlier, risk-based screening matters.

Family caregivers absorb enormous burden after a breast cancer diagnosis, so routine caregiver support is vital.

Mammography use fell significantly among younger, uninsured, and non-Hispanic White and Asian women from 2002-2022, with the 2009 USPSTF guideline change a likely driver.

Bireociclib plus fulvestrant significantly improved progression-free survival and response rates in advanced HR-positive breast cancer, with manageable safety and consistent benefits across high-risk subgroups.

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred during this February IVBM in Los Angeles.

Rural US patients with breast cancer face higher advanced-stage diagnoses, with Black, Hispanic, uninsured patients and those in Southern regions at greatest risk.

A new meta-analysis links menopausal hormone therapy to higher breast cancer risk with estrogen-progestin therapy, while estrogen-only therapy may lower risk.

Risk-based mammography tailors screening to breast cancer risk, reducing false positives and preventing more deaths than age-based screening.

Sequencing CDK4/6i to the second line rather than the first appears to produce equivalent survival for most patients with meaningfully less treatment burden.

A study of 1.5 million patients suggests that ACA Medicaid expansion reduces breast cancer deaths, especially advanced cases—yet racial and income gaps persist.

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

Sarah M. Lima, PhD, MPH, on how historical redlining continues to shape breast cancer survival disparities through treatment access and innovation.

Study finds breast cancer survival gaps tied to historical redlining narrowed over time, though newer therapies may be widening disparities again.

City St. George’s researchers identified 9 genetic signatures and epigenetic changes driving lapatinib resistance in HER2-positive breast cancer.

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

Standard double reading did not perform as well as artificial intelligence for looking at catching cancer and reduced the rate of breast cancer diagnosis by 12%.

Alongside physician collaboration, patient advocacy is essential to ensure clinical trials and public policy reflect patient-centered outcomes.

Patient–physician collaboration ensures trials reflect outcomes that matter to patients, according to Debra Patt, MD, PhD, MBA, MPH.

Yara Abdou, MD, emphasizes that addressing fertility, survivorship, and quality of life is key to improving outcomes for young patients with breast cancer.

Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care systems, explains Adam Brufsky, MD, PhD.